Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ZW171

Bispecific antibody · Immune activation, directed at mesothelin (MSLN) and CD3 (CD3D) · developed by Zymeworks BC

Phase 1 Most advanced trial (none active)

ZYME Developer

1 Registered trials

What is ZW171?

ZW171 is a bispecific T-cell engager antibody that binds mesothelin on tumor cells and CD3 on cytotoxic T-lymphocytes. It activates and redirects T cells to kill mesothelin-expressing tumor cells. The drug is being studied in mesothelin-expressing advanced cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Targets: mesothelin (MSLN), CD3 (CD3D)
Mechanism: Immune activation, directed at mesothelin (MSLN) and CD3 (CD3D)
Pathways: T-cell activation, cytotoxic T-lymphocyte-mediated killing
Therapy area: Oncology
Developer: Zymeworks BC Inc. (ZYME)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06523803	Phase 1	Mesothelin-expressing Advanced Cancers	Terminated	ZYME

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mesothelin-expressing Advanced Cancers

Other drugs acting on MSLN / CD3D

Tarlatamab FDA approved CT-95 Phase 1 CTIM-76 Phase 1 Xaluritamig Phase 3

More from Zymeworks BC

Zanidatamab Zovodotin Phase 1 ZW191 Phase 1 ZW251 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ZYME page.

Follow ZYME, the company behind ZW171

See ZYME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZYME catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z